In a meta‐analysis of second‐line NSCLC phase II and III trials, ICI treatment benefited OS over docetaxel in EGFR mutation‐positive cases (HR 1.11, 95% CI: 0.80–1.53, p = 0.54) (not shown). This evidence concerns the gene EGFR and non-small cell lung carcinoma.